Evidence map›Paper›PMID 30867310›Full record

ArticleJournal of virology2019

The C-Terminal End of HIV-1 Vpu Has a Clade-Specific Determinant That Antagonizes BST-2 and Facilitates Virion Release.

Shilpi Sharma, Moein Jafari, Amandip Bangar, Karen William, John Guatelli, Mary K Lewinski

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Shilpi SharmaDepartment of Medicine, University of California San Diego, La Jolla, California, USA.
Moein JafariDepartment of Medicine, University of California San Diego, La Jolla, California, USA.
Amandip BangarDepartment of Medicine, University of California San Diego, La Jolla, California, USA.
Karen WilliamDepartment of Medicine, University of California San Diego, La Jolla, California, USA.
John GuatelliDepartment of Medicine, University of California San Diego, La Jolla, California, USA jguatelli@ucsd.edu mlewinski@ucsd.edu.
Mary K LewinskiDepartment of Medicine, University of California San Diego, La Jolla, California, USA jguatelli@ucsd.edu mlewinski@ucsd.edu.
University of California, San Diego · USVA San Diego Healthcare System · US

Funding

UC San Diego Clinical and Translational Research InstituteUL1TR001442 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, HOGARTH, MICHAEL · 2015 to 2024
$88.3M
VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI David Mitchell Smith · 1994 to 2026
$78.4M
HIV-1 Vpu and BST-2/CD317R37AI081668 · NIAID · VETERANS MEDICAL RESEARCH FDN/SAN DIEGO · PI GUATELLI, JOHN C. · 2014 to 2023
$4.8M
HIV-1 Modulation of the Ubiquitinome and Its Effects on Cell-to-Cell TransmissionK08AI112394 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LEWINSKI, MARY KATHLEEN · 2015 to 2019
$971k
Involvement of the C-terminus of HIV-1 Vpu in Enhancement of Virion ReleaseR21AI114397 · NIAID · VETERANS MEDICAL RESEARCH FDN/SAN DIEGO · PI GUATELLI, JOHN C. · 2014 to 2015
$383k
NCATS NIH HHS UL1 TR001442NIAID NIH HHS K08 AI112394NIAID NIH HHS P30 AI036214NIAID NIH HHS R21 AI114397NIAID NIH HHS R37 AI081668
6 · The paper itself

Abstract

The cellular protein bone marrow stromal antigen-2 (BST-2)/tetherin acts against a variety of enveloped viruses by restricting their release from the plasma membrane. The HIV-1 accessory protein Vpu counteracts BST-2 by downregulating it from the cell surface and displacing it from virion assembly sites. Previous comparisons of Vpus from transmitted/founder viruses and between viruses isolated during acute and chronic infection led to the identification of a tryptophan at position 76 in Vpu (W76) as a key determinant for the displacement of BST-2 from virion assembly sites. Although present in Vpus from clades B, D, and G, W76 is absent from Vpus from clades A, C, and H. Mutagenesis of the C-terminal region of Vpu from two clade C viruses led to the identification of a conserved LL sequence that is functionally analogous to W76 of clade B. Alanine substitution of these leucines partially impaired virion release. This impairment was even greater when the mutations were combined with mutations of the Vpu β-TrCP binding site, resulting in Vpu proteins that induced high surface levels of BST-2 and reduced the efficiency of virion release to less than that of virus lacking

Indexed as

Antigens, CDbeta-Transducin Repeat-Containing ProteinsBone Marrow Stromal Antigen 2Cell LineCell MembraneGPI-Linked ProteinsHeLa CellsHIV-1HIV InfectionsHIV SeropositivityHuman Immunodeficiency Virus ProteinsHumansViral Regulatory and Accessory ProteinsVirionViroporin ProteinsVirus AssemblyAntigens, CDbeta-Transducin Repeat-Containing ProteinsBone Marrow Stromal Antigen 2BST2 protein, humanGPI-Linked ProteinsHuman Immunodeficiency Virus ProteinsViral Regulatory and Accessory ProteinsViroporin Proteinsvpu protein, Human immunodeficiency virus 1BST-2host-pathogen interactionshuman immunodeficiency virusmolecular biologyrestriction factorsvirologyvirus-host interactionsVpu

Identifiers

PMID30867310
PMCPMC6532089
OpenAlexW2920799007

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.